STN SEARCH SUMMARY
10/826,729

```
=> d his

     (FILE 'HOME' ENTERED AT 17:18:17 ON 29 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 17:18:30 ON 29 MAR 2005
                E JUGLONE/CN
L1            1 S E3
                E FREDERICAMYCIN-A/CN
                E FREDERICAMYCIN/CN
L2            1 S E5
                E PIN-1/CN
L3            1 S E7

     FILE 'CAPLUS' ENTERED AT 17:20:49 ON 29 MAR 2005
L4         1236 S L1 OR L2
L5           27 S L4 AND PIN?
L6           30 S L4 AND (PIN? OR PPIASE? OR ISOMERASE)
L7           30 S L4 AND (PIN? OR PPIASE? OR ISOMERASE OR PARVULIN)
L8            3 S L7 AND PARVULIN
L10          15 S L4 AND ((CELL W PROLIFERATION) OR (ABNORMAL W CELL W GROWTH) OR
L11         397 S (PIN1 OR PIN-1) OR (PIN W 1)                                    (CANCER))
L12       31466 S (PIN1 OR PIN-1) OR (PIN W 1) OR PIN
L13         169 S L12 AND ISOMERASE
L14         172 S L12 AND (ISOMERASE OR PEPTIDYL OR PARVULIN)
L15          98 S L14 AND (MODULAT? OR INHIBIT? OR ACTIVAT?)
L16           1 S L15 AND COVALENT

=> e juglone/cn
E1            1     JUGLOMYCIN Z/CN
E2            1     JUGLON/CN
E3            1 --> JUGLONE/CN
E4            1     JUGLONE ACETATE/CN
E5            1     JUGLONE BENZYL ETHER/CN
E6            1     JUGLONE GLUCOSIDE/CN
E7            1     JUGLONE HYDROXYLASE/CN
E8            1     JUGLONE METHYL ETHER/CN
E9            1     JUGLONE OXIDOREDUCTASE/CN
E10           1     JUGLONE REDUCTASE/CN
E11           1     JUGLONE, 2,3,7-TRIMETHOXY-/CN
E12           1     JUGLONE, 2,3,7-TRIMETHOXY-, ACETATE/CN

=> s e3; d
L1            1 JUGLONE/CN



L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   481-39-0  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   1,4-Naphthalenedione, 5-hydroxy- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1,4-Naphthoquinone, 5-hydroxy- (8CI)
CN   Juglone (6CI)
```

```
OTHER NAMES:
CN   1,4-Dihydro-1,4-dioxo-5-hydroxynaphthalene
CN   5-Hydroxy-1,4-naphthalenedione
CN   5-Hydroxy-1,4-naphthoquinone
CN   5-Hydroxynaphthoquinone
CN   8-Hydroxy-1,4-naphthoquinone
CN   Akhnot
CN   C.I. 75500
CN   C.I. Natural Brown 7
CN   Juglon
CN   NSC 153189
CN   NSC 34266
CN   NSC 622948
CN   Nucin
CN   Regianin
CN   Walnut Extract
FS   3D CONCORD
MF   C10 H6 O3
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,
       CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*,
       HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT,
       NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2,
       USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**
         (**Enter CHEMLIST File for up-to-date regulatory information)


=> e fredericamycin/cn
E1            1     FRECIDE/CN
E2            1     FRED/CN
E3            0 --> FREDERICAMYCIN/CN
E4            1     FREDERICAMYCIN <SYM65>-CYCLODEXTRIN 1:2 COMPLEX/CN
E5            1     FREDERICAMYCIN A/CN
E6            1     FREDERICAMYCIN A TETROL/CN
E7            1     FREDERICAMYCIN B/CN
E8            1     FREDERICAMYCIN C/CN
E9            1     FREDERICAMYCIN TETROL/CN
E10           1     FREDERICAMYCIN TETROL TRIPOTASSIUM SALT/CN
E11           1     FREDERICAMYCIN-3-CARBOXALDEHYDE/CN
E12           1     FREDERICON A/CN

=> s e5;d
L2            1 "FREDERICAMYCIN A"/CN


L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   80455-68-1  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Spiro[2H-benz[f]indene-2,8'-[8H]cyclopent[g]isoquinoline]-1,1',3,5,8(2'H)-
     pentone, 6',7'-dihydro-4,9,9'-trihydroxy-6-methoxy-3'-[(1E,3E)-1,3-
     pentadienyl]-, (2S)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
```

```
CN   Spiro[2H-benz[f]indene-2,8'-[8H]cyclopent[g]isoquinoline]-1,1',3,5,8(2'H)-
     pentone, 6',7'-dihydro-4,9,9'-trihydroxy-6-methoxy-3'-(1,3-pentadienyl)-,
     [S-(E,E)]-
OTHER NAMES:
CN   Fredericamycin A
CN   NSC 305263
FS   STEREOSEARCH
MF   C30 H21 N O9
CI   COM
LC   STN Files:   ADISINSIGHT, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMINFORMRX, CIN,
       DDFU, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, NAPRALERT, PHAR, PROMT,
       SYNTHLINE, TOXCENTER, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.
Double bond geometry as shown.


=> s e7; d
L3           1 "PIN1 (HUMAN CELL LINE HELA GENE PIN1)"/CN


L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   479476-95-4  REGISTRY
ED   Entered STN:  17 Jan 2003
CN   Pin1 (human cell line HeLa gene PIN1) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1997: PN: WO03095618 TABLE: 1 claimed protein
CN   2064: PN: WO03091391 FIGURE: 20 unclaimed protein
CN   2841: PN: WO03038130 FIGURE: 3 claimed protein
CN   387: PN: WO2004038376 TABLE: 5 unclaimed protein
CN   GenBank AAC50492
CN   GenBank AAC50492 (Translated from: GenBank U49070)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL


=> file caplus


=> d l8 2-3

L8   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2005:54187  CAPLUS
DN   142:149781
TI   Use of chaperonin PPIase for enhancement of poorly expressed
     proteins and immobilization of the proteins for drug screening
IN   Ideno, Akira; Furuya, Masahiro
PA   Sekisui Chemical Co., Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 41 pp.
     CODEN: JKXXAF
```

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005013067	A2	20050120	JP 2003-181394	20030625
PRAI	JP 2003-181394		20030625		

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:276736 CAPLUS
DN 129:51272
TI Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone
AU Hennig, Lars; Christner, Claudia; Kipping, Marc; Schelbert, Birte; Rucknagel, Karl Peter; Grabley, Susanne; Kullertz, Gerd; Fischer, Gunter
CS Enzymology of Protein Folding, Max-Planck Research Unit, Halle/Saale, D-06120, Germany
SO Biochemistry (1998), 37(17), 5953-5960
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l10 10-15

L10 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:499158 CAPLUS
DN 121:99158
TI The inhibitory action of juglone on tumor cell multiplication
AU Zhang, Yeping; Yang, Zhibo; Jing, Yongkui; Xu, Shaohui
CS Dep. Pharmacol., Shenyang Coll. Pharm., Shenyang, Peop. Rep. China
SO Shenyang Yaoxueyuan Xuebao (1993), 10(4), 271-4
CODEN: SYXUE3; ISSN: 1000-1727
DT Journal
LA Chinese

L10 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:152406 CAPLUS
DN 116:152406
TI Preparation of LH-RH analogs as hormone-dependent neoplasm inhibitors
IN Schally, Andrew Victor; Janaky, Tamas; Juhasz, Atilla; Bajusz, Sandor
PA USA
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 450461	A2	19911009	EP 1991-104730	19910326
	EP 450461	A3	19920311		
	EP 450461	B1	19950906		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	ES 2076393	T3	19951101	ES 1991-104730	19910326
	CA 2039908	AA	19911007	CA 1991-2039908	19910405

	AU 9174106	A1	19911010	AU 1991-74106	19910405
	AU 638319	B2	19930624		
	HU 57235	A2	19911128	HU 1991-1116	19910405
	JP 04224600	A2	19920813	JP 1991-72936	19910405
	ZA 9104552	A	19920624	ZA 1991-4552	19910614
	WO 9222322	A1	19921223	WO 1991-US4264	19910614
	W: FI, KR, NO				
	NO 9304541	A	19940207	NO 1993-4541	19931210
PRAI	US 1990-505517	A	19900406		
	WO 1991-US4264	A	19910614		

OS MARPAT 116:152406

L10 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:221606 CAPLUS
DN 108:221606
TI Dioxobenz[5,6]isoindolo[2,1-b]isoquinolyl derivatives, procedure for their preparation, formulations containing them, and their use as anticancer agents
IN Phillipps, Gordon Hanley; Jones, Paul Spencer; Cooper, Martin Edward
PA Glaxo Group Ltd., UK
SO Ger. Offen., 22 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3725185	A1	19880204	DE 1987-3725185	19870729
	NO 8702963	A	19880201	NO 1987-2963	19870715
	NL 8701768	A	19880216	NL 1987-1768	19870727
	DK 8703921	A	19880130	DK 1987-3921	19870728
	FI 8703289	A	19880130	FI 1987-3289	19870728
	AU 8776203	A1	19880204	AU 1987-76203	19870728
	AU 604731	B2	19910103		
	CN 87105778	A	19880224	CN 1987-105778	19870728
	CN 1015059	B	19911211		
	GB 2195636	A1	19880413	GB 1987-17864	19870728
	GB 2195636	B2	19900530		
	JP 63093783	A2	19880425	JP 1987-186790	19870728
	HU 46011	A2	19880928	HU 1987-3460	19870728
	HU 201936	B	19910128		
	SE 8702986	A	19890129	SE 1987-2986	19870728
	ES 2007666	A6	19890701	ES 1987-2210	19870728
	US 4851399	A	19890725	US 1987-78716	19870728
	CH 672489	A	19891130	CH 1987-2885	19870728
	BE 1002110	A4	19900710	BE 1987-839	19870728
	AT 8701909	A	19910415	AT 1987-1909	19870728
	SU 1676445	A3	19910907	SU 1987-4203501	19870728
	FR 2602233	A1	19880205	FR 1987-10763	19870729
	FR 2602233	B1	19900817		
	ZA 8705592	A	19880831	ZA 1987-5592	19870729
	AT 8702563	A	19911015	AT 1987-2563	19871008
	JP 02000187	A2	19900105	JP 1989-33893	19890215
PRAI	GB 1986-18398	A	19860729		
	GB 1987-10608	A	19870505		

OS CASREACT 108:221606; MARPAT 108:221606

L10 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:49879 CAPLUS
DN 106:49879
TI Fredericamycin A derivatives
IN Hasegawa, Hiroshi; Yokoi, Koichi; Narita, Masa; Asaoka, Takemitsu; Kukita, Kenichi; Ishizeki, Seiji; Nakajima, Toshiaki
PA S. S. Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61044867	A2	19860304	JP 1984-166283	19840808
	JP 03004548	B4	19910123		
PRAI	JP 1984-166283		19840808		

OS CASREACT 106:49879

L10 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:497256 CAPLUS
DN 105:97256
TI Fredericamycin A derivatives
IN Hasegawa, Hiroshi; Yokoi, Koichi; Narita, Masa; Asaoka, Takemitsu; Kukita, Kenichi; Ishizeki, Seiji; Nakajima, Toshiaki
PA S. S. Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61044868	A2	19860304	JP 1984-166683	19840809
	JP 03031193	B4	19910502		
PRAI	JP 1984-166683		19840809		

L10 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1968:28389 CAPLUS
DN 68:28389
TI Mitotic abnormalities produced by juglone in Ehrlich ascites tumor cells
AU Okada, Tadashi A.; Roberts, Eugene; Brodie, Arnold F.
CS City of Hope Med. Center, Duarte, CA, USA
SO Proceedings of the Society for Experimental Biology and Medicine (1967), 126(2), 583-8
CODEN: PSEBAA; ISSN: 0037-9727
DT Journal
LA English

=> d l10 abs

L10 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AB The invention provides a method for treating a Pin1-associated state in a subject including administering to a subject an effective amount of a fredericamycin A compound such that the Pin1-associated state is treated. In another aspect, the invention includes the above-described method, wherein

the Pin1-associated state is a cyclin D1 elevated state, neoplastic transformation, and/or tumor growth. In an embodiment, the invention provides the above-described methods, wherein the Pin1-associated state is colon cancer, breast cancer, a sarcoma, a malignant lymphoma, and/or esophageal cancer. The invention also provides a method for treating cyclin D1 overexpression in a subject including administering to a subject an effective amount of a combination of a fredericamycin A compound and a hyperplastic inhibitory agent such that the cyclin D1 overexpression is treated.

=> d l10 10 abs

L10 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AB The IC50 values of juglone for inhibiting the growth of various lines of cultured mouse cancer cells were: 13.8 <SYM109>g/mL (HeLa cell), 9.8 <SYM109>g/mL (P388 cell), 7.1 <SYM109>g/mL (P388/ADR cell) and 11.6 <SYM109>g/mL (S180 cell). Juglone's inhibition of S180 cells was cytocidal and concentration-dependent in nature.

=> d l10 5-10

L10 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:257994 CAPLUS
DN 134:266570
TI Preparation of luteinizing hormone releasing hormone analogs having a cytotoxic moiety
IN Janaky, Tamas; Juhasz, Attila; Bajusz, Sandor; Schally, Andrew V.
PA The Administrators of the Tulane Educational Fund, USA
SO U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 505,517, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6214969	B1	20010410	US 1993-8186	19930125
	NO 9304541	A	19940207	NO 1993-4541	19931210
PRAI	US 1988-260994	B2	19881021		
	US 1989-404667	B2	19890907		
	US 1990-505517	B2	19900406		
	WO 1991-US4264	A	19910614		

OS MARPAT 134:266570
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:535357 CAPLUS
DN 133:144904
TI Caspase cascade-based methods for identifying therapeutically effective antineoplastic agents, compounds so identified, and pharmaceutical compositions
IN Weber, Eckard; Tseng, Ben Y.; Drewe, John; Cai, Sui Xiong
PA Cytovia, Inc., USA
SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000045165	A1	20000803	WO 2000-US2329	20000201
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1151295	A1	20011107	EP 2000-907081	20000201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US 1999-118102P	P	19990201		
US 1999-454595	A	19991207		
WO 2000-US2329	W	20000201		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:126257 CAPLUS
DN 126:233190
TI Antitumor promoting effects of naphthoquinone derivatives on short term Epstein-Barr early antigen activation assay and in mouse skin carcinogenesis
AU Kapadia, Govind J.; Balasubramanian, Venkataraman; Tokuda, Harukuni; Konoshima, Takao; Takasaki, Midori; Koyama, Junko; Tagahaya, Kiyoshi; Nishino, Hoyoku
CS Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Howard University, Washington, D.C. 20059, USA
SO Cancer Letters (Shannon, Ireland) (1997), 113(1,2), 47-53
CODEN: CALEDQ; ISSN: 0304-3835
PB Elsevier
DT Journal
LA English

L10 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:257730 CAPLUS
DN 125:10466
TI Further model studies related to fredericamycin A: analogs in which ring C is expanded to six atoms, and an examination of the diastereoselectivity of radical spirocyclization
AU Clive, Derrick L. J.; Kong, Xianglong; Paul, Christine Chua
CS Chem. Dep., Univ. Alberta, Edmonton, AB, T6G 2G2, Can.
SO Tetrahedron (1996), 52(17), 6085-116
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English

L10 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:678592 CAPLUS
DN 123:74386
TI Preliminary study of the effect of selected Chinese natural drugs on human ovarian cancer cells
AU Yu, Jing Jie; Reed, Eddie
CS National Cancer Institute, National Institutes Health, Bethesda, MD, 20892, USA
SO Oncology Reports (1995), 2(4), 571-5
CODEN: OCRPEW; ISSN: 1021-335X
PB Oncology Reports
DT Journal
LA English

L10 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:499158 CAPLUS
DN 121:99158
TI The inhibitory action of juglone on tumor cell multiplication
AU Zhang, Yeping; Yang, Zhibo; Jing, Yongkui; Xu, Shaohui
CS Dep. Pharmacol., Shenyang Coll. Pharm., Shenyang, Peop. Rep. China
SO Shenyang Yaoxueyuan Xuebao (1993), 10(4), 271-4
CODEN: SYXUE3; ISSN: 1000-1727
DT Journal
LA Chinese

not in vivo

=> d l10 3-4

L10 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:777766 CAPLUS
DN 139:292095
TI Preparation of fredericamycin derivatives for use in treating cancer
IN Abel, Ulrich; Simon, Werner
PA Bioleads GmbH, Germany; Biofrontera Discovery GmbH
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080582	A2	20031002	WO 2003-EP2922	20030320
	WO 2003080582	A3	20041209		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10248451	A1	20031009	DE 2002-10248451	20021017
	CA 2480468	AA	20031002	CA 2003-2480468	20030320
	EP 1503988	A2	20050209	EP 2003-714862	20030320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI DE 2002-10213580 A 20020326
DE 2002-10248451 A 20021017
WO 2003-EP2922 W 20030320
OS MARPAT 139:292095

L10 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:594670 CAPLUS
DN 137:150218
TI Methods of inhibiting Pin1-associated states using a fredericamycin A compound
IN Ping, Lu Kun; Fischer, Gunter
PA Pintex Pharmaceuticals, Iceland
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060436	A2	20020808	WO 2001-US50597	20011221
	WO 2002060436	A3	20030123		
	WO 2002060436	C1	20030424		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	CA 2432981	AA	20020808	CA 2001-2432981	20011221
	US 2003055072	A1	20030320	US 2001-27864	20011221
	EP 1363620	A2	20031126	EP 2001-994482	20011221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

	JP 2004533992	T2	20041111	JP 2002-560628	20011221
PRAI	US 2000-257412P	P	20001222		
	US 2001-342572P	P	20011220		
	US 2001-27865	A	20021221		
	WO 2001-US50597	W	20011221		

OS MARPAT 137:150218

=> d l10 11-12 abs

L10 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
GI

AB Title peptides X-R1-R2-R3-Ser-R5-R6(Q)-Leu-Arg-Pro-R10-NH2 (I; R1 = pyroglutamic acid residue, 3-(2-naphthyl)-D-alanine residue; R2 = His, 4-chloro-D-phenylalanine residue; R3 = Trp, D-Trp, 3-(3-pyridyl)-D-alanine residue; R5 = Tyr, Arg; R6 = D-Lys, D-Orn; R10 = Gly, D-Ala; X = H, C2-5 alkanoyl; Q = cytotoxic moiety Q4, AQ3, B(Q1)2, B(AQ2)2; A = NH(CH2)nCO, OC(CH2)nCO where n = 2,6; B = HNCH2(CH2)mCH(NH)n(CH2)nCO where m,n = 0, 1; A and B are bound to R6 via CO and CO moiety of A is bonded to an amino group on B for B(AQ2)2; Q1 = D- or L-4-[bis(2-chloroethyl)amino]-phenylalanine residue, cyclopropylcarbonyl, aziridine-2-carbonyl; etc.; Q2 = Q1, doxorubicin residue, etc.; Q3 = Q2, methotrexoyl, etc.; Q4 - Q1, methotrexoyl] were prepared as LH-RH analogs useful as hormone-dependent neoplasm inhibitors. Thus, title LH-RH analog II was prepared via coupling of [D-Lys]6LH-RH (preparation via standard solid phase method using a benzhydrylamine resin, Boc-Gly-OH, and the appropriate protected amino acids given) and anthraquinone 2-methylhemiglutarate (preparation from 2-(hydroxymethyl)anthraquinone and glutaric anhydride given). II at 10 <SYM109>g/mL in vitro gave 71% inhibition of 3H-thymidine incorporation into DNA in MCF-7 human breast cancer cells.

L10 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
GI

AB The title derivs. I [R1, R2 = H, OH, OP(O)(OH)(OR4); R4 = H, alkyl (un)substituted by OH, alkoxy, cyclic ether, cycloalkyl, R4 = alkenyl, cycloalkyl, aryl, aralkyl, aroylalkyl; <SYM179>1 of R1 and R2 = OP(O)(OH)(OR4); R3 = H, halo, Me] and their salts, useful as anticancer agents (no data), were prepared by 5 methods. A suspension of I (R1 = R3 = H, R2 = ICH2CO2) in THF was treated with H2O and HCl and the mixture stirred and refluxed 18 h to give I (R1 = R3 = H, R2 = OH) which, in THF, was added to NaH in THF and the whole treated with ClP(O)(OPr)2 in THF to give I [R1 = R3 = H, R2 = OP(O)(OPr)2]. This reacted with NaI in refluxing MeCOEt to give I [R1 = R3 = H, R2 = OP(O)(OPr)(ONa)] (II). A dry powder for injection comprised a weight II equivalent to 100 mg acid, 8.8 mg tri-Na citrate, and 0.2 mg citric acid per vial.

=> d l10 13-14 abs

L10 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Stable fredericamycin A derivs. I (R = H, C1-4 alkyl; R1 = C1-4 alkyl), useful as neoplasm inhibitors, were prepared Thus, fredericyamin A (II) was reduced over 10% Pd/C in THF at room temperature for 10 h, then stirred with Ac2O for 1 h to give 80% III. III was heated with MeI and Ag2O in Me2CO for 1 h to give 56.3% I (R = R1 = Me), whose i.p. administration prolonged the lives of mice transplanted with Ehrlich cancer cells (5

+ 106 cells/animal) in a dose dependent manner. A saline solution of III was more stable than that of II.

L10 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Stable fredericamycin A derivs. I and II (R = H, EtO2C, acyl; R1 = alkyl), useful as neoplasm inhibitors and bactericides, were prepared Thus, fredericamycin A (III, R = H)(IV) was treated with EtO2CCl in pyridine at 0° under stirring to give 83.% III (R = EtO2C), which was then treated with MeI and Ag2O in anhydrous dioxane at 75-80° under stirring to give 56.3% II (R = EtO2C, R1 = Me), whose i.p. administration prolonged the lives of mice transplanted with Ehrlich cancer cells (5 + 106 cells/animal) in a dose dependent manner. The title compds. also showed stronger antibacterial activities against Saccharomyces ruxii and Piricularia oryzae than IV in vitro.

=> d l16

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:934473 CAPLUS
DN 141:388653
TI Methods of treating pin1 associated disorders by covalent modification ofactive site residues
IN Tibbitts, Thomas
PA Pintex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004094601	A2	20041104	WO 2004-US11954	20040416
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005004024	A1	20050106	US 2004-826729	20040416
PRAI	US 2003-463810P	P	20030417		

=> d l15 95-98

L15 ANSWER 95 OF 98 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:276736 CAPLUS
DN 129:51272
TI Selective inactivation of parvulin-like peptidyl -prolyl cis/trans isomerases by juglone
AU Hennig, Lars; Christner, Claudia; Kipping, Marc; Schelbert, Birte; Rucknagel, Karl Peter; Grabley, Susanne; Kullertz, Gerd; Fischer, Gunter
CS Enzymology of Protein Folding, Max-Planck Research Unit, Halle/Saale, D-06120, Germany
SO Biochemistry (1998), 37(17), 5953-5960
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 96 OF 98 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:217908 CAPLUS
DN 129:2867
TI The mitotic peptidyl-prolyl isomerase, Pin1, interacts with Cdc25 and Plx1
AU Crenshaw, Donna G.; Yang, Jing; Means, Anthony R.; Kornbluth, Sally
CS Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, 27710, USA
SO EMBO Journal (1998), 17(5), 1315-1327
CODEN: EMJODG; ISSN: 0261-4189
PB Oxford University Press
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 97 OF 98 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:203534 CAPLUS
DN 128:319840
TI The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins
AU Shen, Minhui; Stukenberg, P. Todd; Kirschner, Marc W.; Lu, Kun Ping
CS Cancer Biology Program, Div. Hematology/Oncology, Dep. Med., Beth Israel Deaconess Med. Center and Div. on Aging, Harvard Med. Sch., Boston, MA, 02215, USA
SO Genes & Development (1998), 12(5), 706-720
CODEN: GEDEEP; ISSN: 0890-9369
PB Cold Spring Harbor Laboratory Press
DT Journal
LA English
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 98 OF 98 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:421344 CAPLUS
DN 127:30677
TI NIMA-interacting proteins and cDNA sequence from human
IN Hunter, Tony; Lu, Kun Ping
PA Salk Institute for Biological Studies, USA
SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9717986	A1	19970522	WO 1996-US17334	19961028
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5972697	A	19991026	US 1995-555912	19951113
	CA 2235225	AA	19970522	CA 1996-2235225	19961028
	AU 9711158	A1	19970605	AU 1997-11158	19961028
	EP 880359	A1	19981202	EP 1996-941949	19961028
	R: CH, DE, FR, GB, LI				
	US 5952467	A	19990914	US 1998-66074	19980424
	US 6596848	B1	20030722	US 1999-275900	19990324
	US 2005033032	A1	20050210	US 2003-616410	20030708
	US 2005049404	A1	20050303	US 2003-648631	20030825
	US 2004101896	A1	20040527	US 2003-687361	20031015
	US 2005027107	A1	20050203	US 2003-716379	20031117
PRAI	US 1995-555912	A	19951113		
	WO 1996-US17334	W	19961028		
	US 1998-66074	A3	19980424		
	US 1999-275900	A1	19990324		
	US 2003-616410	A1	20030708		

=> d l15 abs 96

L15 ANSWER 96 OF 98 CAPLUS COPYRIGHT 2005 ACS on STN
AB The cis/trans peptidyl-prolyl isomerase, Pin1
, is a regulator of mitosis that is well conserved from yeast to man. Here, we demonstrate that depletion of Pin1-binding proteins from Xenopus egg exts. results in hyperphosphorylation and inactivation of the key mitotic regulator, Cdc2/cyclin B. We show biochem. that this phenotype is a consequence of Pin1 interaction with critical upstream regulators of Cdc2/cyclin B, including the Cdc2-directed phosphatase, Cdc25, and its known regulator, Plx1. Although Pin1 could interact with Plx1 during interphase and mitosis, only the phosphorylated, mitotically active form of Cdc25 was able to bind Pin1, an event we have recapitulated using in vitro phosphorylated Cdc25. Taken together, these data suggest that Pin1 may modulate cell cycle control through interaction with Cdc25 and its activator, Plx1.